Core Viewpoint - BioCryst Pharmaceuticals has agreed to acquire Astria Therapeutics for an implied value of $13 per share, totaling approximately $700 million in enterprise value, with the transaction expected to close in the first quarter of 2026 [1][2]. Acquisition Details - The acquisition will consist of $8.55 in cash and 0.59 shares of BioCryst stock for each share of Astria [1]. - Astria focuses on therapies for allergic and immunologic diseases, with its lead product candidate being Navenibart, an injectable monoclonal antibody for hereditary angioedema (HAE) prophylaxis [3][4]. Strategic Importance - Navenibart's clinical profile and administration schedule could significantly improve treatment options compared to existing therapies [3]. - BioCryst's established infrastructure in HAE is expected to enhance the market reach of Navenibart, which will complement its existing portfolio of oral and potential injectable therapies for HAE [4][5]. Market Potential - The addressable market for Navenibart includes over 5,000 patients currently treated with injectable prophylaxis, potentially driving double-digit revenue growth for BioCryst over the next decade [6]. - The transaction is anticipated to be accretive to adjusted operating profit in the first full year following Navenibart's expected launch [6]. Funding Mechanism - BioCryst has secured a debt commitment letter for a strategic financing facility with Blackstone, with a total capacity of up to $550 million to fund the acquisition [7][8]. - The cash portion of the acquisition will be financed through existing cash and a portion of the Blackstone facility [8]. Shareholder Impact - Following the acquisition, Astria stockholders will own approximately 15% of the pro forma equity in the combined company [8].

Navenibart (STAR-0215) for Hereditary Angioedema (HAE) - Navenibart is designed for a better patient experience with potential for Q3M and Q6M administration[9, 5] - The estimated HAE market is expected to grow from $3.2 billion in 2024 to $5.4 billion in 2030[14] - A global Phase 3 pivotal trial is ongoing to assess the efficacy and safety of Navenibart for Q3M and Q6M administration in HAE, with a 3:3:3:2 randomization (n=135)[17, 18] - ALPHA-STAR Phase 1b/2 results showed Navenibart achieved 91-95% attack rate reduction, 25-67% attack-free rate, 95-96% reduction in moderate and severe attack rate, and 91-94% reduction in attacks requiring rescue medication[29] - QSP model-predicted change in time-normalized monthly HAE attack rate shows 91-93% reduction with 600mg Q6M, 96-99% reduction with 600mg loading and 300mg Q3M, and 83-87% reduction with 600mg Q3M[41] - Market research indicates Navenibart Q3M & Q6M is expected to gain 46% total patient share from switches and 53% from newly initiating preventative therapies[50, 53] STAR-0310 for Atopic Dermatitis (AD) - The estimated moderate-to-severe AD market is expected to grow from $7 billion in 2023 to $26 billion in 2030[59] - STAR-0310 is a high affinity, next-generation anti-OX40 antibody with potential for low volume, infrequent SC delivery and a patent expiring in 2044[74, 75] - STAR-0310 has an estimated mean half-life of 26 days in cynomolgus monkeys, suggesting potential for administration as infrequently as once every 6 months in humans[87, 88] - A Phase 1a trial of STAR-0310 in healthy subjects has been initiated, with initial results expected in Q3 2025[91] Financial Position - As of March 31, 2025, the company had $295.1 million in cash, cash equivalents, and short-term investments[97] - The company expects its cash to fund operations into mid-2027[97]